Global Cephalosporin Drugs Market Size (2024 - 2029)

The cephalosporin drugs market is projected to experience significant growth, driven by an increasing demand for antimicrobials and a rising prevalence of infectious diseases. The market's expansion is further supported by enhanced funding for research and development of antibiotics, alongside the strategic development of new cephalosporin products. Despite challenges such as stringent regulatory approvals and potential side effects, the market is expected to benefit from the growing consumption and availability of cephalosporin drugs.

Market Size of Global Cephalosporin Drugs Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
CAGR
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 2.75 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Low

Major Players

Global Cephalosporin Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Cephalosporin Drugs Market Analysis

The cephalosporin drugs market is expected to grow at registering a CAGR of 2.75% during the forecast period (2022-2027).

The cephalosporin market was damaged by COVID-19's effects on the pharmaceutical industry's worldwide supply chain. However, numerous antibiotics are currently explored and extensively used as a COVID-19 treatment after being initially used to treat COVID-19. Various studies have found that the higher cephalosporin consumption rate and use ratio have made lower morbidity and mortality caused by COVID-19 than another antibacterial. For instance, a research study titled "Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study" published in the PLOS ONE Journal in May 2021, Ceftaroline Fosamil, a cephalosporin antibiotic, has been proposed as a powerful inhibitor of SARS-primary CoV-2's protease responsible for processing the polyprotein translated from viral RNA. Cephalosporin has been widely used to prevent secondary bacterial infection. Also, the cephalosporins in combinations with macrolides and quinolones may be potentially effective against COVID-19 (SARS-CoV-2). Therefore, there are in vitro and in vivo studies going on to evaluate the potential of generations of cephalosporin for COVID-19. As a result, the COVID-19 market had a significant influence and is anticipated to grow over the coming years.

The market is expected to grow due to the increasing demand for anti-microbials in various indications, the rising prevalence of infectious diseases such as HIV and tuberculosis, and the increase in funding for the development of antibiotics. For instance, according to the October 2021 report of the World Health Organization, tuberculosis is present in all countries and all age groups, and approximately 10 million people fell ill with tuberculosis (TB) all over the world in 2020, of which eight countries account for two-thirds of the total TB cases in 2021, with India leading the count, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. It has also been reported that there is a rapid spread of various infectious diseases that is fueling market growth. Moreover, according to a survey conducted by the World Health Organization for the period from 24 January 2022 to 06 February 2022, approximately 12,368 people were positive for influenza viruses. Out of these, 8,423 (68.1%) people were typed as influenza A and 3,945 (31.9%) people as influenza B. Furthermore, 171 (6.4%) were influenza A (H1N1), and 2,483 (93.6%) were influenza A (H3N2). Thus, the growing burden of infectious diseases is expected to increase the demand for cephalosporin, thereby driving the market growth. The market growth is also attributed to the increase in consumption of cephalosporin, easier availability, and a rise in demand for over-the-counter drugs.

Over the forecast period, the market for cephalosporin pharmaceuticals is anticipated to grow as a result of an increase in funding for research and development (R&D) of cephalosporin drugs and antibiotics. For instance, in June 2020, The International Federation of Pharmaceutical Manufacturers and Association established the AMR Action Fund, which will invest more than USD 1 billion over the coming years to support the development of urgently required new antibiotics. The fund is supported by major pharmaceutical companies and also has the support of other stakeholders. It also aims to support the development of market circumstances that will support long-term antibiotic R&D. Similarly, in June 2021, the pharmaceutical company BioVersys, located in Switzerland, received funding of up to USD 4.35 million for its efforts to create a new class of antibiotics.

Additionally, there are also companies involved in the strategic development of new products; for example, in September 2021, Lincoln Pharmaceuticals Limited intends to introduce cephalosporin medicines soon. with the acquisition of the facility in Mehsana, Gujarat, and will invest Rs. 30 crores in the modernization and capacity expansion of the cephalosporin plant. The acquisition and capital expenditures will be paid for out of internal accruals. In February 2020, Shionogi & Co. Ltd announced that FETROJA (cefiderocol) was now available in the United States for patients 18 years of age or older who have limited or no alternative treatment options for the treatment of complicated urinary tract infections (cUTIs). FETROJA (cefiderocol) is a cephalosporin antibiotic with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore.

Hence, all these factors may help the cephalosporin drugs market to witness high growth over the forecast period. However, stringent regulatory approval and side effects associated with cephalosporin restrain the market growth.

Cephalosporin Drugs Industry Segmentation

As per the scope of this report, cephalosporins are part of the beta-lactams group and work by interfering with the synthesis of the bacterial cell wall. Some may be given orally, but most are given by injection. They are typically the second-choice antibiotic, and their main uses are in pneumonia, septicemia, meningitis, sinusitis, and UTI treatment. Despite their second-line usage, cephalosporins have a broader spectrum of activity and are more potent than penicillin. The Cephalosporin Drugs Market is segmented by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Prescription Type (Prescription Drugs and OTC Drugs) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Generation
First-generation
Second-generation
Third-generation
Fourth-generation
Fifth-generation
By Prescription Type
Prescription Drugs
OTC Drugs
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Cephalosporin Drugs Market Size Summary

The cephalosporin drugs market is poised for growth, driven by the increasing demand for antimicrobials to combat infectious diseases and the rising prevalence of conditions such as HIV and tuberculosis. The market experienced disruptions due to the COVID-19 pandemic, which affected the global pharmaceutical supply chain. However, the pandemic also highlighted the efficacy of cephalosporins in treating secondary bacterial infections and their potential role in COVID-19 treatment, thereby boosting their consumption. The market is further supported by significant investments in research and development, aimed at developing new antibiotics and enhancing existing cephalosporin formulations. Strategic initiatives by pharmaceutical companies, including product launches and acquisitions, are expected to strengthen market positions and expand the availability of cephalosporin drugs.

North America is anticipated to witness substantial market growth due to the high prevalence of infectious diseases and increased healthcare expenditure. The availability of broad-spectrum cephalosporins, such as cefuroxime, and their use in treating various infections contribute to market expansion. The market's growth is also fueled by the rising consumption of cephalosporins, easier access to these drugs, and the growing demand for over-the-counter medications. Despite challenges such as stringent regulatory approvals and potential side effects, the market remains competitive, with numerous players engaging in collaborations and clinical trials to drive innovation and address antibiotic resistance. The fragmented nature of the market, with both small and large companies vying for market share, underscores the dynamic and evolving landscape of the cephalosporin drugs market.

Explore More

Global Cephalosporin Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Demand for Anti-microbials in Various Indications

      2. 1.2.2 Rising Prevalence of Infectious Diseases

      3. 1.2.3 Increase in Funding for the Development of Antibiotics

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulatory Guidelines

      2. 1.3.2 Side Effects Associated with Cephalosporin

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 By Generation

      1. 2.1.1 First-generation

      2. 2.1.2 Second-generation

      3. 2.1.3 Third-generation

      4. 2.1.4 Fourth-generation

      5. 2.1.5 Fifth-generation

    2. 2.2 By Prescription Type

      1. 2.2.1 Prescription Drugs

      2. 2.2.2 OTC Drugs

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Cephalosporin Drugs Market Size FAQs

The Global Cephalosporin Drugs Market is projected to register a CAGR of 2.75% during the forecast period (2024-2029)

Baxter International, GlaxoSmithKline PLC, Lupin Pharmaceuticals Inc., Pfizer Inc. and Teva Pharmaceutical Industries Ltd are the major companies operating in the Global Cephalosporin Drugs Market.

Cephalosporin Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)